Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
11
×
life sciences
national blog main
clinical trials
boston blog main
boston
boston top stories
fda
deals
national top stories
new york blog main
san diego blog main
san francisco blog main
startups
investing
san diego top stories
atlas venture
cancer
decibel therapeutics
dyne therapeutics
gene therapy
hearing loss
kaleido biosciences
myotonic dystrophy type 1
new enterprise associates
rare disease drugs
regenerative medicine
san diego
abide therapeutics
achaogen
adams street partners
adeno-associated virus
akouos
allergan
allosteric
amylin pharmaceuticals
antibiotics
astellas pharma
astellas pharmaceuticals
atopic dermatitis
What
medicines
11
×
therapeutics
11
×
drug
developing
ipo
new
ago
approved
biotech
clinic
company
disease
diseases
drugs
dyne
fda
genetic
hearing
loss
molecules
muscle
rare
regenerative
research
targets
treat
years
abide
adding
address
adds
affects
affordable
aiming
aims
allosteric
americans
amounts
appointed
approach
Language
unset
Current search:
medicines
×
therapeutics
×
biotech
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@techcrunch.com
5 years ago
CB Therapeutics’ lab-grown cannabinoids could unlock new medicines and make others affordable